These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26231377)

  • 1. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Mansell SE; Kim RB; Tirona RG; Beaton MD
    Drug Metab Dispos; 2015 Oct; 43(10):1484-90. PubMed ID: 26231377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
    Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
    Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
    Jamwal R; de la Monte SM; Ogasawara K; Adusumalli S; Barlock BB; Akhlaghi F
    Mol Pharm; 2018 Jul; 15(7):2621-2632. PubMed ID: 29792708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis.
    Yoshimine Y; Uto H; Kumagai K; Mawatari S; Arima S; Ibusuki R; Mera K; Nosaki T; Kanmura S; Numata M; Tamai T; Moriuchi A; Tsubouchi H; Ido A
    Oncol Rep; 2015 Apr; 33(4):1657-66. PubMed ID: 25607821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.
    Nitta SI; Hashimoto M; Kazuki Y; Takehara S; Suzuki H; Oshimura M; Akita H; Chiba K; Kobayashi K
    AAPS J; 2018 Apr; 20(3):61. PubMed ID: 29858698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls.
    Da Silva HE; Arendt BM; Noureldin SA; Therapondos G; Guindi M; Allard JP
    J Acad Nutr Diet; 2014 Aug; 114(8):1181-94. PubMed ID: 24631112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation.
    Zeng H; Lin Y; Gong J; Lin S; Gao J; Li C; Feng Z; Zhang H; Zhang J; Li Y; Yu C
    Chem Biol Interact; 2019 Aug; 308():185-193. PubMed ID: 31132328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
    Li K; Zhao S; Zhang L; Wu X; Shu P; Wang Y; Feng H; Gu Z; Han Hsu H
    Drug Metab Dispos; 2014 May; 42(5):839-43. PubMed ID: 24595680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.
    Alonso C; Fernández-Ramos D; Varela-Rey M; Martínez-Arranz I; Navasa N; Van Liempd SM; Lavín Trueba JL; Mayo R; Ilisso CP; de Juan VG; Iruarrizaga-Lejarreta M; delaCruz-Villar L; Mincholé I; Robinson A; Crespo J; Martín-Duce A; Romero-Gómez M; Sann H; Platon J; Van Eyk J; Aspichueta P; Noureddin M; Falcón-Pérez JM; Anguita J; Aransay AM; Martínez-Chantar ML; Lu SC; Mato JM
    Gastroenterology; 2017 May; 152(6):1449-1461.e7. PubMed ID: 28132890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
    Kawaguchi T; Itou M; Taniguchi E; Sata M
    Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet-induced non-alcoholic fatty liver disease affects expression of major cytochrome P450 genes in a mouse model.
    Chiba T; Noji K; Shinozaki S; Suzuki S; Umegaki K; Shimokado K
    J Pharm Pharmacol; 2016 Dec; 68(12):1567-1576. PubMed ID: 27757967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH.
    Amrutkar M; Cansby E; Nuñez-Durán E; Pirazzi C; Ståhlman M; Stenfeldt E; Smith U; Borén J; Mahlapuu M
    FASEB J; 2015 Apr; 29(4):1564-76. PubMed ID: 25609431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease.
    du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S
    Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
    Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
    Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH.
    Takeuchi M; Sakasai-Sakai A; Takata T; Ueda T; Takino J; Tsutsumi M; Hyogo H; Yamagishi S
    Med Hypotheses; 2015 May; 84(5):490-3. PubMed ID: 25697114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A8 Production in CXCR2-Expressing CD11b+Gr-1high Cells Aggravates Hepatitis in Mice Fed a High-Fat and High-Cholesterol Diet.
    Mukai K; Miyagi T; Nishio K; Yokoyama Y; Yoshioka T; Saito Y; Tanaka S; Shigekawa M; Nawa T; Hikita H; Sakamori R; Yoshihara H; Imai Y; Hiramatsu N; Tatsumi T; Takehara T
    J Immunol; 2016 Jan; 196(1):395-406. PubMed ID: 26608915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.